RVP

Business Context and Reporting Period

Company: Retractable Technologies, Inc. (RVP)
Reporting Period: Quarter ended March 31, 2026 (Q1 2026)
Business Overview: The Company designs, develops, manufactures, and markets safety syringes and other safety medical products. Operations are based in Little Elm, Texas, with significant manufacturing reliance on Chinese suppliers (61.0% of products in Q1 2026). The Company operates in a single reportable segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 13.5% to $7.18 million. Domestic sales fell 20.0% due to lower unit sales and decreased average selling prices, while international sales increased 42.4% driven by EasyPoint needle sales.
• Gross Margin Deterioration: The Company reported a gross loss of $0.84 million compared to a near-breakeven gross profit in Q1 2025. This was driven by a $0.86 million inventory write-down for products approaching expiration and higher operating costs relative to sales volume.
• Investment Performance: The net loss improved significantly year-over-year primarily due to a $0.19 million unrealized gain on debt and equity securities in Q1 2026, contrasting with a $7.16 million unrealized loss in Q1 2025.
• Operating Expenses: Increased 14.0% to $5.33 million, largely due to non-recurring charitable product donations of approximately $0.59 million and consultant fees of $0.30 million.
• Tariff Impact: Tariff expenses were minimal ($11.6 thousand) in Q1 2026 due to mitigation efforts, though prevailing tariff rates on Chinese imports remain at 110% for syringes and needles.

Outlook, Risks, and Management Commentary

• Workforce Reduction: In April 2026 (subsequent to period end), the Company reduced its workforce by approximately 16%, targeting $2.2 million in annual savings. One-time separation costs of $0.12 million were incurred.
• Tariff Risks: Significant uncertainty remains regarding trade policy. A 100% Section 301 tariff on syringes/needles from China remains, plus a new 10% ad valorem duty. The Company is increasing domestic production of 0.5mL syringes to mitigate reliance on imports, with commercial quantities expected in H2 2026.
• Liquidity: Management believes cash reserves and liquidation of investments ($32.85 million) are sufficient to fund operations for at least 12 months. However, liquidity is expected to decline materially over the next 1-3 years due to tariff costs and increased domestic manufacturing expenses.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to previously reported material weaknesses, though improvements to the monthly close process have been initiated.
• Government Contracts: The Company continues to amortize income from a Technology Investment Agreement (TIA) with the U.S. government ($1.48 million recognized in Q1 2026). Future government orders are unpredictable.

Investor Verification Checklist

• Inventory Valuation: Verify the $0.86 million inventory write-down and the remaining inventory levels ($16.4 million) given the expiration risks cited.
• Tariff Exposure: Assess the impact of the 110% tariff rate on future cost of goods sold and the timeline for domestic production ramp-up.
• Liquidity Runway: Confirm the sufficiency of the $32.85 million investment portfolio to cover operating losses if sales do not recover.
• Internal Control Remediation: Monitor progress on fixing material weaknesses in internal controls over financial reporting.
• Customer Concentration: Note that 47.1% of sales came from just two significant customers in Q1 2026.